Cellyan Biotechnology Co., Ltd (HKPD) shareholders
HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Aug 7, 2026Score 3/30
$1.52−0.09 (-5.30%)
Close on Nov 17, 2026Market cap $24.93MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1.5%
0M of 16M shares
Institutional holders
6
3 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Liying Wang Joint filing with TUTU Business Services Limited (65.00%) | 7,150,000 | 65.00% | 13D (active) | Oct 6, 2025 |
| Lap Sun Wong | 6,244,961 | 56.77% | 13G (passive) | Mar 31, 2025 |
| Atlantic Health Century International Group | 617,850 | 5.62% | 13G (passive) | Mar 31, 2025 |
| Pacific Health Century International Group | 617,850 | 5.62% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HKPD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| StoneX Group Inc. | 102,310 | 0.63% | $52.36K | +62,915 | 0.00% |
| Jane Street Group, LLC | 49,087 | 0.30% | $18.65K | New | 0.00% |
| Hrt Financial LP | 41,824 | 0.26% | $15.00K | New | 0.00% |
| XTX Topco Ltd | 38,930 | 0.24% | $14.79K | New | 0.00% |
| Clear Street Group Inc. | 12,019 | 0.07% | $4.57K | – | 0.00% |
| UBS Group AG | 1,081 | 0.01% | $411 | +971 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 1.5% | 3 / 2 | 0 / 1 | 0M | 0M |
| Q1 2026 | 4 | 0M | 0.4% | 0 / 0 | 3 / 0 | 0M | 0M |
| Q4 2025 | 4 | 0M | 0.5% | 2 / 1 | 0 / 0 | 0M | 0M |
| Q3 2025 | 2 | 0M | 0.1% | 1 / 0 | 1 / 4 | 0M | 0M |
| Q2 2025 | 6 | 0M | 0.4% | 3 / 1 | 2 / 1 | 0M | 0M |
| Q1 2025 | 4 | 0M | 0.3% | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chenyu Andy Liang | CEO and Director | – | – | Jun 8, 2026 |
| Zifeng Wang | Chief Strategy Officer | – | – | Jun 9, 2026 |
| Shu Liu | CFO | – | – | Jun 8, 2026 |
| Kam Leung CHAN | Director | – | – | Jun 12, 2026 |
| Lap Sun Wong | Director | 18,468 | 0.11% | Jun 10, 2026 |
| Jingyan Wu | Director | – | – | Jun 8, 2026 |
| Mike Yao Zhou | Director | – | – | Jun 8, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.57%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-91.4%
From 0M shares
Short volume, 20 days
41.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cellyan Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 354,881 shares on Sep 11, 2026 over the last 90 days.
See a number that looks wrong?